Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer
With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.
Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer
Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.
Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer
September 29th 2019The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.
Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer
More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).
Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer
Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.
Frontline Nivolumab/Ipilimumab Combo Improves OS in Advanced NSCLC
September 28th 2019The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.
Niraparib Improves PFS as Frontline Maintenance in Ovarian Cancer
Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.
Frontline Veliparib Shows Intriguing PFS Findings in VELIA Trial
The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.
Telaglenastat Plus Everolimus Emerges as Novel Approach in Metastatic RCC
Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.
Cediranib/Olaparib Combo Shows Promise in Platinum-Resistant Ovarian Cancer
The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.
Atezolizumab Plus Bevacizumab Impresses in Unresectable HCC
Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.
Pemigatinib Active as Second-Line Treatment for FGFR2+ Cholangiocarcinoma
More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.
Apalutamide Linked to OS Benefit in Nonmetastatic CRPC
September 27th 2019The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.
Selinexor Triplet Highly Active in Relapsed Myeloma
September 16th 2019The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.
Dr. Richardson on Results of the HORIZON Trial in Relapsed/Refractory Multiple Myeloma
September 16th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.
Dr. Mateos on Frail Patients With Multiple Myeloma in the ARROW Trial
September 16th 2019Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.
Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma
September 16th 2019AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.
Kumar Discusses Path Forward for Venetoclax in Myeloma
September 16th 2019Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.
.jpg?fit=crop&auto=format)
